Zehragül Ergül
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Zehragül Ergül has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ajda Coker-Gurkan
Department of Molecular Biology and Genetics, Istanbul Kultur University, Istanbul, Turkey
1 shared publication - Deniz Coşkun
Science and Literature Faculty, Department of Molecular Biology and Genetics, Istanbul Kultur University, Atakoy Campus, 34156, Istanbul, Turkey
1 shared publication - Elif Damla Arisan
Institute of Biotechnology, Gebze Technical University, Gebze, 41400, Kocaeli, Türkiye
1 shared publication - Gülnihal Bozdağ
Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Yeditepe University, Istanbul 34755, Türkiye
1 shared publication - Narcin Palavan-Unsal
Istanbul Kultur University
1 shared publication - Ozge Rencuzogullari
Istanbul Kultur University
1 shared publication
Latest Publications
- 8 November 2018
- Published by Springer Nature in Molecular Biology Reports
- Vol. 45 (6) , 2175-2184
Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells
Diclofenac is a preferential cyclooxygenase 2 inhibitor (COX-2) and member of non-steroidal anti-inflammatory drugs (NSAIDs). Inflammation is one of the main reason of poor prognosis of colon cancer cases; thereby NSAIDs are potential therapeutic agents in colon cancer therapy. In this study, our aim to understand the potential molecular targets of diclofenac, which may propose new therapeutic targets in HCT 116 (wt p53) and SW480 (mutant p53R273H) colon cancer cells. For this purpose, we identified different response against diclofenac treatment through expression profiles of PI3K/Akt/MAPK signaling axis. Our hypothesis was diclofenac-mediated apoptosis is associated with inhibition of PI3K/Akt/MAPK signaling axis. We found that sub-cytotoxic concentration of diclofenac (400 µM) promoted further apoptosis in HCT 116 cells compared to SW480 colon cancer cells. Diclofenac triggered dephosphorylation of PTEN, PDK, Akt, which led to inhibition of PI3K/Akt survival axis in HCT 116 colon cancer cells. However, diclofenac showed lesser effect in SW480 colon cancer cells. In addition, diclofenac further activated p44/42, p38 and SAPK/JNK in HCT 116 cells compared to SW480 cells.
- 8 November 2018
- Published by Springer Nature in Molecular Biology Reports
- Vol. 45 (6) , 2175-2184
Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells
Diclofenac is a preferential cyclooxygenase 2 inhibitor (COX-2) and member of non-steroidal anti-inflammatory drugs (NSAIDs). Inflammation is one of the main reason of poor prognosis of colon cancer cases; thereby NSAIDs are potential therapeutic agents in colon cancer therapy. In this study, our aim to understand the potential molecular targets of diclofenac, which may propose new therapeutic targets in HCT 116 (wt p53) and SW480 (mutant p53R273H) colon cancer cells. For this purpose, we identified different response against diclofenac treatment through expression profiles of PI3K/Akt/MAPK signaling axis. Our hypothesis was diclofenac-mediated apoptosis is associated with inhibition of PI3K/Akt/MAPK signaling axis. We found that sub-cytotoxic concentration of diclofenac (400 µM) promoted further apoptosis in HCT 116 cells compared to SW480 colon cancer cells. Diclofenac triggered dephosphorylation of PTEN, PDK, Akt, which led to inhibition of PI3K/Akt survival axis in HCT 116 colon cancer cells. However, diclofenac showed lesser effect in SW480 colon cancer cells. In addition, diclofenac further activated p44/42, p38 and SAPK/JNK in HCT 116 cells compared to SW480 cells.